Timothy S. Pardee, M.D., Assistant Professor Internal Medicine-Hematology and Oncology

Timothy S. Pardee, M.D.

Assistant Professor, Hematology & Oncology
Cancer Biology

Clinical Specialties

Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndromes, Hematologic Malignancies

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Email: tspardee@wakehealth.edu

Insurance Accepted »

Education & Training

M.D., University of Buffalo - SUNY , 2003
Ph.D., University of Buffalo - SUNY , 1999
Residency, Internal Medicine, Massachusetts Gen Hosp, 2005
Fellowship, Hematology And Oncology, Stony Brook School of Medicine, 2009

Board Certifications

American Board of Internal Medicine

NPI Number

1740386010

Timothy S. Pardee, M.D.

Assistant Professor, Hematology & Oncology Cancer Biology

Research Interests

cancer/oncogenesis, drugs/therapeutic agents pharm

Contact Information

Academic: 336-745-0424 | Department: 336-716-4464

Email: tspardee@wakehealth.edu

Recent Publications

Puthiyaveetil AG, Reilly CM, Pardee TS, Caudell DL. Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome. Leuk Res. 2013;37(1):112-116.

Jennings-Gee J, Pardee TS, Gmeiner WH. Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. Exp Hematol. 2013;41(2):180-188.

Cook GJ, Pardee TS. Animal models of leukemia: any closer to the real thing?. Cancer Metastasis Rev. 2013;32(1-2):63-76.

Manny JS, Pardee T, Pettenati M, Pang CS. Near-tetraploid/tetraploid acute myeloid leukemia: morphologic, cytogenetic, and prognostic features [abstract]. Mod Pathol. 2012;25(Suppl 2):354A.

Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Blood. 2012;119(15):3561-3570.

Pardee TS. Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction. PLoS One. 2012;7(8):e43185.

Cook GJ, Caudell DL, Elford HL, Pardee T. The novel ribonucleotide reductase inhibitor didox is active against AML with limited toxicities [abstract]. Blood. 2012;120(21):Abstr 1513.

Pardee TS, Zuber J, Lowe SW. Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. Exp Hematol. 2011;39(4):473-485.

Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, Levitan D, Pardee TS, Isom S, Powell BL. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc. 2011;59(10):1837-1846.

Cook GJ, Elford HL, Pardee T. Activity of the novel ribonucleotide reductase inhibitor didox on human and murine models of acute leukemia [abstract]. Blood. 2011;118(21):1553-1554.

Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP10 results in high efficacy against AML and low toxicity [abstract]. Blood. 2011;118(21):1109-1110.

Pardee T, DeFord-Watts LM, Peronto E, Levitan DA, Hurd DD, Kridel S. Altered lipid and mitochondrial metabolism are viable targets in acute leukemia [abstract]. Blood. 2011;118(21):1546.

Pardee T. Over expression of MN1 accelerates leukemia onset and confers resistance to chemotherapy by suppression of p53 and Bim [abstract]. Blood. 2011;118(21):1070.

Chiou V, Tiegs J, Isom S, Pettenati MJ, Lyerly S, Ellis LR, Pardee T, Dmitriy B, Powell BL, Levitan DA. A single institution analysis of incidence of recurrent chromosomal abnormalities in adult ALL patients according to race, gender, and age [abstract]. Blood. 2011;118(21):4869.

Klepin HD, Tooze JA, Geiger AM, Kritchevsky S, Williamson J, Ellis LR, Levitan D, Pardee T, Isom S, Powell BL. Geriatric assessment predicts overall survival among older adults receiving induction chemotherapy for acute myelogenous leukemia [abstract]. Blood. 2010;116(21):653-654.

Pardee T, Mascenik T, Bolemon BH, Cook GJ. Over expression of MN1 confers resistance to chemotherapy in vitro and in vivo [abstract]. Blood. 2010;116(21):427.

Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W. The novel fluoropyrimidine FdUMP[10] is highly active against acute myeloid leukemia [abstract]. Blood. 2010;116(21):1353.

Pardee T, Zuber J, Lowe S. The FLT3 ITD accelerates an already established myeloid leukemia and alters chemotherapy response in vitro and in vivo in a p53 dependent manner [abstract]. Blood. 2009;114(22):685.